Withdrawals due to adverse events · acute gout
NSAIDs showed no clear difference in withdrawals due to adverse events compared with glucocorticoids (moderate certainty).
1 finding from 1 review
RR 2.8 [0.55, 14.22]
Studies not reported
Moderate
Total adverse events · acute gout
NSAIDs probably leads to higher total adverse events compared with glucocorticoids (moderate certainty).
1 finding from 1 review
RR 1.62 [1.03, 2.55]
Studies not reported
Moderate
Function: ≥ 50% improvement in pain with movement at 24 hours · acute gout
NSAIDs showed no clear difference in function: ≥ 50% improvement in pain with movement at 24 hours compared with placebo (low certainty).
1 finding from 1 review
RR 4 [0.5, 31.74]
Studies not reported
Low
Participants' global assessment of treatment: not measured№. of participants: 30 (1 RCT) · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Health‐related quality of life: not measured№. of participants: 30 (1 RCT) · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Withdrawals due to adverse events · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Total adverse events · acute gout
NSAIDs showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
RR 0.2 [0.01, 3.85]
Studies not reported
Low
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Swelling (mean) · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Acute gout attacks · people with chronic gout
1 finding from 1 review
sUA reduction · participants with chronic gout and sUA level > 0.36mmol/L
1 finding from 1 review
Joint pain reduction ‐ not reported · participants with chronic gout and sUA level > 0.36mmol/L
The review found no eligible studies for this question.
1 finding from 1 review
Participant global assessment · participants with chronic gout and sUA level > 0.36mmol/L
The review found no eligible studies for this question.
1 finding from 1 review
Total adverse events · participants with chronic gout and sUA level > 0.36mmol/L
1 finding from 1 review
Tophus regression · participants with chronic gout and sUA level > 0.36mmol/L
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Skim milk enriched with GMP/G600 showed no clear difference in study withdrawals due to adverse events compared with skim milk, plus lactose powder (low certainty).
sUA acid reduction4 ‐ mmol/L at · people with chronic gout
1 finding from 1 review
Joint pain reduction ‐ not reported · people with chronic gout
Global assessment of treatment success · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Total adverse eventsd · people with chronic gout
Skim milk enriched with GMP/G600 showed no clear difference in total adverse eventsd compared with skim milk, plus lactose powder (low certainty).
1 finding from 1 review